These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 11758581

  • 21. Follow-on biologics: data exclusivity and the balance between innovation and competition.
    Grabowski H.
    Nat Rev Drug Discov; 2008 Jun; 7(6):479-88. PubMed ID: 18469828
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
    Gass A, Wilson J.
    Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Drug manufacturers' First Amendment right to advertise and promote their products for off-label use: avoiding a pyrrhic victory.
    Blackwell AE, Beck JM, Dechert, L.L.P, Philadelphia, USA.
    Food Drug Law J; 2003 Mar; 58(3):439-62. PubMed ID: 14626985
    [No Abstract] [Full Text] [Related]

  • 26. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT.
    Mich Law Rev; 2015 Mar; 114(1):107-36. PubMed ID: 26394458
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2008 Sep 29; 73(189):56487-91. PubMed ID: 18985960
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Entry decisions in the generic pharmaceutical industry.
    Morton FM.
    Rand J Econ; 1999 Sep 29; 30(3):421-40. PubMed ID: 10558596
    [Abstract] [Full Text] [Related]

  • 33. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL.
    Food Drug Law J; 2005 Sep 29; 60(2):261-338. PubMed ID: 16094773
    [No Abstract] [Full Text] [Related]

  • 34. Generics battle brand names over mortality of drug patents.
    Betz R.
    J Healthc Resour Manag; 1995 Jul 29; 13(7):35-7. PubMed ID: 10144008
    [No Abstract] [Full Text] [Related]

  • 35. The Food and Drug Administration's regulation of prescription drug manufacturer speech: a First Amendment analysis.
    Evans GW, Friede AI, Pfizer Inc, New York, NY, USA.
    Food Drug Law J; 2003 Jul 29; 58(3):365-437. PubMed ID: 14626984
    [No Abstract] [Full Text] [Related]

  • 36. Correcting Hatch-Waxman.
    Fernandes M.
    Health Aff (Millwood); 2008 Jul 29; 27(3):902-3; author reply 903. PubMed ID: 18475000
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS.
    Seton Hall Law Rev; 2003 Jul 29; 33(2):479-510. PubMed ID: 12715807
    [No Abstract] [Full Text] [Related]

  • 40. Legal issues concerning the promotion of pharmaceutical products on the internet to consumers.
    Reichertz PS.
    Food Drug Law J; 1996 Jul 29; 51(3):355-65. PubMed ID: 11797712
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.